Helping You Make a Difference.
Your commitment to developing new products to help patients fighting cancer is invaluable, and we want to be your partner in this valiant battle.
Our dedicated Oncology Business Unit (OBU) has the staff expertise, global footprint, and robust infrastructure to support your cancer trials from Phase I through post-approval. To deepen our oncology service offerings, Novella Clinical acquired the oncology operations of OSI Pharmaceuticals and Prologue Research, a leading oncology-focused CRO with more than a decade of experience, all of whom share a common culture centered on customer service and operational excellence.
We’re proud to have an OBU focused on making a meaningful difference in the lives of people with cancer. And together we will.
Why choose Novella’s Oncology Business Unit?
- Exclusively focused on oncology clinical research
- Deep oncology experience crossing all functional groups
- Strong investigator relationships
- Extensive investigator database capturing site-specific performance metrics and operational details
- An infrastructure to support global needs, yet the attention of a niche provider
- Integrated eClinical solutions (i.e. EDC, CTMS, Safety)
- Timely, accurate and open communications ensuring a high level of transparency
- Shared commitment to success